Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | CTSS | P25774 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.51 |
| ▸ | CTSH | P09668 | 1/20 | 0.50 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 7/20 | 0.47 |
| ▸ | MC4R | P32245 | 4/20 | 0.46 |
| ▸ | MC5R | P33032 | 2/20 | 0.46 |
| ▸ | MC3R | P41968 | 2/20 | 0.46 |
| ▸ | MC1R | Q01726 | 2/20 | 0.46 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13144378 | 0.93 | IL23R (0.53) | C5AR1IL23RMC4RMC5RMC3R | |
| SCHEMBL13478176 | 0.92 | IL23R (0.47) | CTSLCTSSCTSKC5AR1CTSH | |
| SCHEMBL13144533 | 0.91 | C5AR1 (0.53) | CTSLCTSSCTSKC5AR1CTSH | |
| SCHEMBL13478184 | 0.90 | C5AR1 (0.48) | CTSLCTSSCTSKC5AR1CTSH | |
| SCHEMBL13144366 | 0.89 | C5AR1 (0.51) | CTSLCTSSCTSKC5AR1IL23R | |
| SCHEMBL13144373 | 0.88 | CXCL8 (0.49) | C5AR1IL23R | |
| SCHEMBL13144545 | 0.87 | MC4R (0.55) | IL23RMC4RMC5RMC3RMC1R | |
| SCHEMBL13478177 | 0.87 | MC4R (0.55) | IL23RMC4RMC5RMC3RMC1R | |
| SCHEMBL13144882 | 0.85 | IL23R (0.51) | C5AR1IL23RMC4RMC5RMC3R | |
| SCHEMBL13144540 | 0.85 | MC4R (0.53) | IL23RMC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267639-A1 | TREATMENT OF OSTEOARTHRITIS | PROMICS PTY LIMITED (AU) | 2010-10-21 | — | — | US | disclosed |
| US-7659246-B2 | Treatment of osteoarthritis | PROMICS PTY LIMITED (AU) | 2010-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267639-A1 | TREATMENT OF OSTEOARTHRITIS | C5AR2, C5AR1, C3AR1 | CTSL 488/4885CTSS 671/4885CTSK 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.